Novo Nordisk markets a weight-loss drug in France this Tuesday, October 8
Credit : Pexels
To combat obesity, the Danish laboratory Novo Nordisk is launching the marketing of the drug Wegovy this Tuesday, October 8 in France. This disease affects more than 8 million adults and the number of people suffering from it is increasing, especially among young adults. This disease is more widespread in the overseas departments, where it affects 23% of the population in Guadeloupe and 28% in Martinique, compared to 17% in France.
What is Wegovy?
This treatment, available only by prescription, imitates a natural hormone that stimulates insulin, GLP-1, responsible for the feeling of satiety. The active substance in Wegovy, semaglutide, is the same as that found in the diabetes medication Ozempic. Its dosage is more concentrated for this treatment against obesity. It is injected with an injector pen weekly.
Who is it aimed at?
This weight loss medication concerns obese people, those whose initial body mass index (BMI) is greater than or equal to 35 kg/m². Patients must be at least 12 years old and at most 65 years old according to the recommendations of the National Medicines Safety Agency.
How to get it prescribed?
The first prescription is made by a specialist in endocrinology, diabetology and nutrition. Renewals can be done by a general practitioner. This new treatment is not reimbursed. The Novo Nordisk subsidiary estimated the price of Wegovy between 9 and 12 euros.
What are the recommendations?
Treatment occurs when the patient has made changes in their eating habits and in the practice of sporting activities, but is unable to achieve their goals.
What are the results?
This weight loss drug shows promising clinical results, with around 15% weight loss on average.
Side effects?
The treatment is accompanied by undesirable effects such as nausea, diarrhea or even vomiting.
